



Ref: Bio/Acts/ CS/ SE/ Ltrs- NSE/04
October 24, 2013

Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100 India
T 91 80 2808 2808
F 91 80 2852 3423

www.biocon.com

The National Stock Exchange of India Limited
Exchange Plaza,
Bandra – Kurla Complex,
Bandra (East),
Mumbai- 400 051

“By Fax, Mail & Courier”

Kind Attn: Mr. Hari K.

Dear Sir,

Subject: - Un-audited Financial Results for the quarter and half year ended September 30, 2013

We are pleased to inform you that the Board of Directors of the Company has approved the un-audited financial results for the quarter and half year ended September 30, 2013, at its meeting held on October 24, 2013, in Bangalore. In compliance with Clause 41 of the Listing Agreement, we are forwarding the following documents for your record:

A. Financial Results:

Un-audited results as per the format specified in the listing agreement, for

- a) Biocon Limited and its Subsidiaries (consolidated)
- b) Biocon Limited (standalone)
- c) Biocon Limited - segment report (consolidated)
- d) Limited review report by Statutory auditors

B. A press announcement relating to the results.

Kindly take this intimation on record.

Thanking you,
Yours faithfully,
For Biocon Ltd,

Kiran Kumar G
Company Secretary
E: Kiran.Kumar@biocon.com
T: +91 80 2808 2037

by “Courier”
by Fax To NSE: 022 – 2659 8237 / 38
NSE: cm1ist@nse.co.in

Encl. No of sheets:

BIOCON LIMITED
Registered office: 20th KM HOSUR ROAD, ELECTRONIC CITY P.O., BANGALORE - 560 100
STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2013

Part I		(Rs in Lakhs)					
Sl. No.	Particulars	3 months ended 30.09.2013	Preceding 3 months ended 30.06.2013	Corresponding 3 months ended 30.09.2012	Year to date figures for current period ended 30.09.2013	Year to date figures for previous period ended 30.09.2012	Previous Year ended 31.03.2013
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from operations						
	a) Net Sales/ Income from Operations (Net of excise duty)	73,421	69,476	59,240	1,42,897	1,16,326	2,42,760
	b) Other Operating Income	660	593	3,623	1,253	4,205	5,770
	Total income from operations (net)	74,081	70,069	62,863	1,44,150	1,20,531	2,48,530
2	Expenses						
	a) Cost of materials consumed	27,971	26,982	22,872	54,953	45,727	1,00,189
	b) Purchases of stock in trade	3,618	2,327	1,014	5,945	3,173	6,931
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	(2,092)	1,057	1,656	(1,035)	864	(2,652)
	d) Employee benefits expense	11,310	11,530	9,457	22,840	18,584	38,944
	e) Depreciation and amortisation expenses	5,009	4,825	4,461	9,834	8,730	17,930
	f) Other expenses (net)	15,688	12,969	12,591	27,871	24,640	50,820
	Total Expenses	61,504	59,690	52,051	1,20,408	1,01,718	2,12,162
3	Profit from operations before other income, finance costs and exceptional items (1-2)	12,577	10,379	10,812	23,742	18,813	36,368
4	Other Income	1,173	2,248	1,331	2,635	2,923	5,266
5	Profit from ordinary activities before finance costs and exceptional items (3+4)	13,750	12,627	12,143	26,377	21,736	41,634
6	Finance Costs	34	38	107	72	428	810
7	Profit from ordinary activities after finance costs before exceptional items (5-6)	13,716	12,589	12,036	26,305	21,308	40,824
8	Exceptional items (net) (refer note 2 and 3 below)	-	-	-	-	-	20,191
9	Profit from ordinary activities before tax (7+8)	13,716	12,589	12,036	26,305	21,308	61,015
10	Tax Expense	3,189	2,971	3,042	6,160	4,415	9,750
11	Net profit for the period / year (9-10)	10,527	9,618	8,994	20,145	16,893	51,265
12	Minority interest	(312)	(268)	(29)	(580)	(48)	(383)
13	Net profit after tax and minority interest (11+12)	10,215	9,350	8,965	19,565	16,845	50,882
14	Paid-up equity share capital (Face value of Rs.5 each)	10,000	10,000	10,000	10,000	10,000	10,000
15	Reserve excluding revaluation reserves as per balance sheet of previous accounting year						2,59,373
16	Earnings per share (of Rs 5 each) (not annualised)						
	(a) Basic	5.21	4.77	4.59	9.98	8.61	25.99
	(b) Diluted	5.17	4.73	4.56	9.90	8.54	25.75
	See accompanying note to the financial results						
Part II							
Select information for the period							
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	Number of shares	7,80,51,554	7,80,75,854	7,80,75,854	7,80,51,554	7,80,75,854	78,075,854
	Percentage of shareholding	39.03%	39.04%	39.04%	39.03%	39.04%	39.04%
2	Promoters and promoter group shareholding						
	a) Pledged / encumbered						
	Number of shares	40,000	-	-	40,000	-	-
	Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	0.03%	-	-	0.03%	-	-
	Percentage of shares (as a % of the total share capital of the Company)	0.02%	-	-	0.02%	-	-
	b) Non-encumbered						
	Number of shares	12,19,08,446	12,19,24,146	12,19,24,146	12,19,08,446	12,19,24,146	12,19,24,146
	Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	99.97%	100%	100%	99.97%	100%	100%
	Percentage of shares (as a % of the total share capital of the Company)	60.95%	60.96%	60.96%	60.95%	60.96%	60.96%



BIOCON LIMITED
Consolidated Statement of Assets and Liabilities

(All amounts in Indian Rupees in Lakhs)

	<u>As at</u> <u>September 30, 2013</u> (Unaudited)	<u>As at</u> <u>March 31, 2013</u> (Audited)
A EQUITY AND LIABILITIES		
1 Shareholders' Funds		
(a) Share capital	10,000	10,000
(b) Reserves and surplus	2,82,945	2,59,463
Sub total-Shareholders' funds	<u>2,92,945</u>	<u>2,69,463</u>
2 Minority interest	7,110	6,530
3 Non-current liabilities		
(a) Long-term borrowings	33,538	16,397
(b) Deferred tax liability (net)	3,605	4,122
(c) Other long-term liabilities	48,796	42,372
(d) Long-term provisions	634	396
Sub total-Non-current liabilities	<u>86,573</u>	<u>63,287</u>
4 Current liabilities		
(a) Short-term borrowings	6,909	8,482
(b) Trade payables	39,297	34,547
(c) Other current liabilities	33,785	34,653
(d) Short-term provisions	10,433	24,652
Sub total-Current liabilities	<u>90,424</u>	<u>1,02,334</u>
TOTAL - EQUITY AND LIABILITIES	<u><u>4,77,052</u></u>	<u><u>4,41,614</u></u>
B ASSETS		
1 Non-current assets		
(a) Fixed assets	2,04,667	1,81,068
(b) Goodwill on consolidation	1,216	1,216
(c) Non-current investments	6,457	6,445
(d) Long-term loans and advances	30,327	24,834
(e) Other non-current assets	5,241	4,051
Sub total-Non-current assets	<u>2,47,908</u>	<u>2,17,614</u>
2 Current assets		
(a) Current investments	47,563	52,207
(b) Inventories	42,286	39,844
(c) Trade receivables	58,352	50,969
(d) Cash and cash equivalents	65,848	67,285
(e) Short term loans and advances	6,229	8,142
(f) Other current assets	8,866	5,553
Sub total-Current assets	<u>2,29,144</u>	<u>2,24,000</u>
TOTAL - ASSETS	<u><u>4,77,052</u></u>	<u><u>4,41,614</u></u>





2/18



BIOCON LIMITED
Registered office: 20th KM HOSUR ROAD, ELECTRONIC CITY P.O., BANGALORE - 560 100
STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2013


Part I		(Rs in Lakhs)					
Sl. No.	Particulars	3 months ended 30.09.2013 (also refer note 5 below)	Preceding 3 months ended 30.06.2013 (also refer note 5 below)	Corresponding 3 months ended 30.09.2012	Year to date figures for current period ended 30.09.2013 (also refer note 5 below)	Year to date figures for previous period ended 30.09.2012	Previous Year ended 31.03.2013
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from operations						
	a) Net Sales/ Income from Operations (Net of excise duty)	53,417	52,289	46,140	1,05,706	89,300	1,83,748
	b) Other Operating Income	2,524	2,247	4,667	4,771	6,251	10,052
	Total income from operations (net)	55,941	54,536	50,807	1,10,477	95,551	1,93,800
2	Expenses						
	a) Cost of materials consumed	22,990	22,757	19,288	45,747	39,019	82,999
	b) Purchases of stock in trade	3,400	2,068	1,504	5,468	3,801	8,570
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	(2,329)	1,122	1,819	(1,207)	1,130	(1,790)
	d) Employee benefits expense	6,589	6,578	5,524	13,167	10,853	22,762
	e) Depreciation and amortisation expenses	3,021	2,898	2,342	5,919	4,725	9,508
	f) Other expenses (net)	12,393	10,554	9,825	22,947	18,912	40,690
	Total Expenses	46,064	45,977	40,302	92,041	78,440	1,62,739
3	Profit from operations before other income, finance costs and exceptional items (1-2)	9,877	8,559	10,505	18,436	17,111	31,061
4	Other Income	2,030	2,686	968	4,716	2,560	5,147
5	Profit from ordinary activities before finance costs and exceptional items (3+4)	11,907	11,245	11,473	23,152	19,671	36,208
6	Finance Costs	24	22	17	46	73	123
7	Profit from ordinary activities after finance costs before exceptional items (5-6)	11,883	11,223	11,456	23,106	19,598	36,085
8	Exceptional items (refer note 3 below)	-	-	-	-	-	1,385
9	Profit from ordinary activities before tax (7+8)	11,883	11,223	11,456	23,106	19,598	34,700
10	Tax Expense	2,895	2,450	2,620	5,345	3,878	7,130
11	Net profit for the period / year (9-10)	8,988	8,773	8,836	17,761	15,720	27,570
12	Impact of scheme of merger for earlier period (refer note 5 below)	554	-	-	554	-	-
13	Profit for the period after giving impact of scheme of merger for earlier year (11+12)	9,542	8,773	8,836	18,315	15,720	27,570
14	Paid-up equity share capital (Face Value of Rs.5 each)	10,000	10,000	10,000	10,000	10,000	10,000
15	Reserve excluding revaluation reserves as per balance sheet of previous accounting year						2,10,594
16	Earnings per share (of Rs 5 each) (not annualised)						
	(a) Basic (after giving impact of scheme of merger for earlier year)	4.87	4.48	4.51	9.34	8.03	14.08
	(b) Diluted (after giving impact of scheme of merger for earlier year)	4.83	4.44	4.49	9.27	7.97	13.95
	(c) Basic (before giving impact of scheme of merger for earlier year)	4.58	4.48	4.51	9.06	8.03	14.08
	(d) Diluted (before giving impact of scheme of merger for earlier year)	4.55	4.44	4.49	8.99	7.97	13.95
	See accompanying note to the financial results						
Part II							
Select information for the period							
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	Number of shares	7,80,51,554	7,80,75,854	7,80,75,854	7,80,51,554	7,80,75,854	78,075,854
	Percentage of shareholding	39.03%	39.04%	39.04%	39.03%	39.04%	39.04%
2	Promoters and promoter group shareholding						
	a) Pledged/encumbered						
	Number of shares	40,000	-	-	40,000	-	-
	Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	0.03%	-	-	0.03%	-	-
	Percentage of shares (as a % of the total share capital of the Company)	0.02%	-	-	0.02%	-	-
	b) Non-encumbered						
	Number of shares	12,19,08,446	12,19,24,146	12,19,24,146	12,19,08,446	12,19,24,146	121,924,146
	Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	99.97%	100.00%	100.00%	99.97%	100.00%	100.00%
	Percentage of shares (as a % of the total share capital of the Company)	60.95%	60.96%	60.96%	60.95%	60.96%	60.96%




BIOCON LIMITED
Standalone Statement of Assets and Liabilities

(All amounts in Indian Rupees in Lakhs)

	<u>As at</u> <u>September 30, 2013</u> (Unaudited)	<u>As at</u> <u>March 31, 2013</u> (Audited)
A EQUITY AND LIABILITIES		
1 Shareholders' Funds		
(a) Share capital	10,000	10,000
(b) Reserves and surplus	2,28,443	2,10,684
Sub total-Shareholders' funds	<u>2,38,443</u>	<u>2,20,684</u>
2 Non-current liabilities		
(a) Long-term borrowings	3,238	3,996
(b) Deferred tax liabilities (net)	3,054	3,020
(c) Other long-term liabilities	13,343	10,830
Sub total-Non-current liabilities	<u>19,635</u>	<u>17,846</u>
3 Current liabilities		
(a) Short-term borrowings	6,283	7,727
(b) Trade payables	31,007	26,504
(c) Other current liabilities	7,612	6,794
(d) Short-term provisions	7,326	21,768
Sub total-Current liabilities	<u>52,228</u>	<u>62,793</u>
TOTAL - EQUITY AND LIABILITIES	<u><u>3,10,306</u></u>	<u><u>3,01,323</u></u>
B ASSETS		
1 Non-current assets		
(a) Fixed Assets	1,03,278	90,260
(b) Non-current investments	14,486	16,599
(c) Long -term loans and advances	43,042	47,128
(d) Other non-current assets	340	-
Sub total-Non-current assets	<u>1,61,146</u>	<u>1,53,987</u>
2 Current assets		
(a) Current investments	42,813	45,298
(b) Inventories	40,636	35,887
(c) Trade receivables	46,352	42,698
(d) Cash and cash equivalents	10,766	17,925
(e) Short -term loans and advances	7,853	5,104
(f) Other current assets	740	424
Sub total-Current assets	<u>1,49,160</u>	<u>1,47,336</u>
TOTAL - ASSETS	<u><u>3,10,306</u></u>	<u><u>3,01,323</u></u>



4/18





BIOCON LIMITED

Registered office : 20TH KM HOSUR ROAD, ELECTRONIC CITY P.O., BANGALORE - 560 100

SEGMENT DETAILS OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE

QUARTER AND SIX MONTH PERIOD ENDED SEPTEMBER 30, 2013

<u>Particulars</u>	3 months ended 30.09.2013 (Unaudited)	Preceding 3 months ended 30.06.2013 (Unaudited)	Corresponding 3 months ended 30.09.2012 (Unaudited)	Year to date figures for current period ended 30.09.2013 (Unaudited)	Year to date figures for previous period ended 30.09.2012 (Unaudited)	Previous Year ended 31.03.2013 (Audited)
(Rs. in Lakhs)						
Segment revenue						
a. Pharma	54,991	54,341	49,688	1,09,332	94,861	1,91,831
b. Contract Research & Manufacturing Services	19,567	16,034	13,711	35,601	26,836	58,829
Total	74,558	70,375	63,399	1,44,933	1,21,697	2,50,660
Less: Inter-segment revenue	477	306	536	783	1,166	2,130
Net sales / Income from continuing operations	74,081	70,069	62,863	1,44,150	1,20,531	2,48,530
Segment results						
Profit before interest, depreciation and tax from each segment						
a. Pharma	22,915	21,813	20,482	44,728	37,491	75,444
b. Contract Research & Manufacturing Services	7,532	5,394	5,268	12,926	10,014	21,081
Total	30,447	27,207	25,750	57,654	47,505	96,525
Less: Interest	34	38	107	72	428	810
Depreciation and amortisation	5,009	4,825	4,461	9,834	8,730	17,930
Unallocated corporate expenses	12,861	12,003	10,477	24,078	19,962	42,227
Unallocated corporate income	(1,173)	(2,248)	(1,331)	(2,635)	(2,923)	(5,266)
Profit before tax and before exceptional items	13,716	12,589	12,036	26,305	21,308	40,824
Capital employed						
a. Pharma	1,36,455	1,33,267	1,23,920	1,36,455	1,23,920	1,28,336
b. Contract Research & Manufacturing Services	59,119	54,113	34,473	59,119	34,473	55,045
c. Unallocable	1,04,481	1,00,773	86,770	1,04,481	86,770	92,612
d. Minority interest	(7,110)	(6,796)	(428)	(7,110)	(428)	(6,530)
Total capital employed	2,92,945	2,81,357	2,44,735	2,92,945	2,44,735	2,69,463



5/18

Notes:

1. The unaudited financial results of the Company and the unaudited consolidated financial results for the quarter and six months ended September 30, 2013 have been subjected to limited review by the statutory auditors. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 24, 2013.

2. During the year ended March 31, 2012, based on an evaluation of the prevalent regulatory framework, industry practices and ethics/governance requirements relating to clinical trials and the regulatory submissions already initiated / filed, Biocon SA, a wholly owned subsidiary of the Company (together referred to as 'Biocon'), had determined that it had continuing obligations to complete clinical development and regulatory activities relating to Biocon's Biosimilar Insulin portfolio comprising of Biosimilar Insulin and Biosimilar Insulin Analogs. Accordingly, pursuant to the termination of the customer contract in March 2012, Biocon deferred the remainder of the upfront amounts received from the customer, to be recognized in the consolidated statement of profit and loss in subsequent periods in line with costs incurred towards such clinical trials and development activities.

In February 2013, Biocon SA entered into an agreement with another customer for the global development and commercialization of Biosimilar Insulin Analogs (the Agreement), granting the customer exclusive rights to commercialize Biosimilar Insulin Analogs in certain countries. The clinical development and regulatory activities in respect of such Biosimilar Insulin Analogs is now being carried out in accordance with the Agreement. As such, Biocon has therefore determined that it does not have continuing obligations for clinical trials and development activities in respect of Biosimilar Insulin Analogs. Accordingly, based on an allocation in proportion of estimated future development spends on these programs, Rs 21,501 lakhs of deferred revenues allocated to Biosimilar Insulin Analogs (net of amounts already recognized in the consolidated statement of profit and loss) was recognized as an exceptional income in the consolidated statement of profit and loss for the year ended March 31, 2013 and is disclosed under exceptional items. Considering that Biocon has continuing obligations in respect of Biosimilar Insulin, the remainder of deferred amounts as at March 31, 2013, of Rs 28,001 lakhs, continues to be recognized in the consolidated statement of profit and loss in line with costs to be incurred towards clinical trials and development activities of Biosimilar Insulin. For the quarter ended June 30, 2013 and September 30, 2013, of the deferred amounts, Rs 338 lakhs and Rs 614 lakhs, respectively have been netted off against expenses incurred towards such clinical trial and development activities.

The statutory auditors of the Company have drawn an Emphasis of Matter in this regard, in their Limited Review report on the consolidated unaudited financial results.

3. Pursuant to certain developments, on a prudent basis, the Company created a provision of Rs 1,385 lakhs and Rs 1,310 Lakhs for diminution, in the value of investments in Iatrica Inc in the standalone and consolidated financial statements, respectively for the year ended March 31, 2013.

4. Total income from operations for quarter and six month period ended September 30, 2012, and for the year ended March 31, 2013 (standalone and consolidated) include Rs 3,064 Lakhs, towards one time income / compensation from few parties.



6/18

5. On July 25, 2012, the Board of Directors of the Company approved a scheme of amalgamation ('the Scheme') of Biocon Biopharmaceuticals Limited ("BBL"), a wholly owned subsidiary, with the Company under sections 391 and 394 of the Companies Act, 1956. During the quarter ended September 30, 2013, the Honorable High Court of Karnataka ('the Court') approved the aforesaid Scheme with Appointed Date as April 1, 2012.

Accordingly, the assets and liabilities, and Deficit in the Statement of Profit and Loss of BBL of Rs 1,028 lakhs as at Appointed Date have been recorded at their carrying values under the Pooling of Interest method as prescribed by Accounting Standard 14 - Accounting for Amalgamation ('AS 14'), and difference between value of investments and the amount of share capital of BBL amounting to Rs 357 lakhs has been debited to the Reserves and Surplus of the Company.

Post receipt of the requisite approvals, the Company has considered the operations of BBL from April 1, 2012 as its own operations. Accordingly, profit after tax amounting to Rs 554 lakhs (net of tax of Rs 579 lakhs), relating to operations of BBL from April 1, 2012 to March 31, 2013, have been accounted for in the standalone results for quarter and six months ended September 30, 2013. Further, the earlier published standalone results for the preceding quarter ended June 30, 2013 have been restated to incorporate the operations of BBL to give effect of the amalgamation.

6. During the quarter ended September 30, 2013, the Company paid dividend of Rs 7.50 per share amounting to Rs 15,000 Lakhs for the year 2012-13 representing 150% dividend.

7. Segment Reporting :

- Standalone financial results: The Company operates in a single business segment of biopharmaceuticals.
- Consolidated financial results: The primary segment reporting has been performed on the basis of business segments. Segments have been identified and reported based on the nature of products, risks and returns, organizational structure and internal financial reporting systems.

8. Information on investor complaints:


	3 months ended 30.09.2013
Pending at the beginning of the quarter	-
Received during the quarter	16
Disposed of during the quarter	16
Remaining unresolved at the end of the quarter	-

9. Prior period / year figures have been reclassified wherever required to conform to the classification of the current period.

For and on behalf of the Board of Directors of Biocon Limited

Kiran Mazumdar Shaw

Kiran Mazumdar Shaw
Chairman and Managing Director



Bangalore,
October 24, 2013



7/18

Limited Review Report

Review Report to
The Board of Directors
Biocon Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Biocon Limited ('the Company') and its subsidiaries, joint venture and associate (together, 'the Group'), for the quarter ended September 30, 2013 (the "Statement"), being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. We did not review revenues (including other income) and assets of Rs. 454 Lakhs and Rs. 114,512 Lakhs respectively, relating to two subsidiaries, and the revenues (including other income) and assets of Rs. 927 Lakhs and Rs. 2,493 Lakhs respectively, being the proportionate share in a joint venture company, included in the accompanying unaudited consolidated financial results for the quarter ended September 30, 2013, whose financial information have been reviewed by other auditors and whose reports have been furnished to us. Our conclusion on the unaudited quarterly financial results, in so far as it relates to such subsidiaries and joint venture company is based solely on the reports of the other auditors.
4. Without qualifying our conclusion, we draw attention to note 2 in the attached statement of unaudited consolidated financial results regarding management's decision to defer recognition of amounts in the consolidated statement of profit and loss, pertaining to payments received pursuant to the Termination & Transition Agreement entered into with a customer for reasons as more fully discussed in the aforesaid note. As further discussed in the said note, out of the deferred amount, Rs. 614 Lakhs has been netted off against expenses incurred during the quarter ended September 30, 2013, towards such clinical trial and development activities. Our auditors' report for the year ended March 31, 2013 also included a matter of emphasis in this regard.
5. Based on our review conducted as above and on consideration of reports of other auditors on the unaudited separate quarterly financial results and on the other financial information of the components, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results prepared in accordance



S.R. BATLIBOI & ASSOCIATES LLP


Chartered Accountants

with recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" [notified pursuant to the Companies (Accounting Standards) Rules, 2006, (as amended)] and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. Batliboi & Associates LLP

ICAI Firm registration number: 101049W

Chartered Accountants



per Aditya Vikram Bhauwala
Partner

Membership No.: 208382



Place: Bangalore

Date: October 24, 2013

9/18

S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants


12th & 13th Floor
"UB City" Canberra Block
No. 24, Vittal Mallya Road
Bengaluru-560 001, India
Tel : +91 80 6727 5000
Fax : +91 80 2210 6000

Limited Review Report

Review Report to
The Board of Directors
Biocon Limited

1. We have reviewed the accompanying statement of unaudited financial results of Biocon Limited ('the Company') for the quarter ended September 30, 2013 (the "Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting", [notified pursuant to the Companies (Accounting Standards) Rules, 2006, (as amended)] and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. Batliboi & Associates LLP
ICAI Firm registration number: 101049W
Chartered Accountants



per Aditya Vikram Bhauwala
Partner
Membership No.: 208382



Place: Bangalore
Date: October 24, 2013

10/18

Sustained Momentum in Biopharma & Research Services delivers 19% growth for Biocon

Revenues at ₹ 1,468 Crores; EBITDA at ₹ 362 Crores; PAT at ₹ 196 Crores

Bengaluru, India: October 24, 2013

Commenting on the results, Chairman and Managing Director, Kiran Mazumdar-Shaw stated,

"Biocon has witnessed a strong performance in the first half of FY14 driven by an increased traction in emerging markets. Immuno-suppressants and Insulins continue to drive growth. This is in part bolstered by capacity expansion of our Insulins plant. Our bio-similar pipeline partnered with Mylan, continues to progress well and we anticipate Indian regulatory approval for our biosimilar Trastuzumab in the near future. The Research Services vertical has delivered a stellar set of numbers, despite an exceptional forex loss in Q2 FY14. This quarter also saw the launch of our second novel biologic, Alzumab™, for Psoriasis in India. Alzumab™ has already seen an encouragingly strong acceptance in the market. The Branded Formulations business has grown ahead of the market but has been muted by business and regulatory challenges. We remain confident that growth will continue across all businesses"

Highlights:

- Revenue growth in H1 FY14 reflects the strength of our differentiated portfolios
 - ❖ Biopharma Business: 21% YoY
 - ❖ Branded Formulations: 13% YoY
 - ❖ Research Services (Syngene and Clinigene): 36% YoY
- Group EBITDA and PAT margins at 25% and 13% respectively
- R&D investments of 82 Crores (9% of Biopharma sales)
- Nationwide roll-out of our 2nd novel biologic, Alzumab™ indicated for psoriasis
- Successfully concluded the India Phase III trial of Biosimilar trastuzumab

Quarterly Business Performance

Financial Highlights: Q2 FY14 (In ₹ Crores)

Revenue : 753		Revenue Breakup:
R&D Expenses: 39	(9% of biopharma sales)	• Biopharma: 447
EBITDA: 188	(EBITDA Margin: 25%)	• Research Services: 188
PAT: 102	(PAT Margin: 14%)	• Branded Formulations: 99
		• Other Income: 11

Biopharma: Small Molecules & Biosimilars

The biopharma portfolio delivered a strong growth of 16% YoY and 13% YoY at Constant Exchange Rate (CER) for H1 FY14 and Q2 FY14 respectively.

Small Molecules

The small molecules portfolio sustained its strong performance through H1 FY14 on the back of steady sales in Immuno-suppressants and Orlistat. Our statins portfolio continues to support these growth drivers with increasing traction in other geographies.

Biosimilars

The Biosimilars portfolio saw a robust growth in H1FY14, driven by the growing demand for generic insulins from emerging markets. We continue to enhance our emerging market footprint to provide a wider access to affordable insulin therapy to diabetics worldwide.

We have successfully completed the India Phase III trial for biosimilar trastuzumab, and have filed for regulatory approval with the Indian authorities. The other programs in the biosimilar development portfolio continue to progress well, and we look forward to bringing them further along the clinical development pathway.

Branded Formulations

The branded formulations vertical grew at 9% YoY this quarter, vis-à-vis the industry growth of 3%. We have seen sustained challenges in the Indian Pharma market (IPM), which de-grew by 2% in September '13. Systemic hurdles led by the chaotic implementation of the recent NPPA guidelines and the trade disputes on margins have resulted in widespread de-stocking & reduced off take.

The highlight for us in Q2 FY14 was the launch of Alzumab™ (Itolizumab), a 'First-in-class' novel biologic therapy for Psoriasis. With a differentiated mechanism of action, Alzumab offers a new treatment paradigm for Psoriasis patients with a less aggressive dosing regimen and a longer treatment free period. The product has been rolled out across the nation, and we have seen encouraging feedback from dermatologists and patients alike. Cytosorb, the only approved extracorporeal cytokine filter commercially available in the EU to safely remove a broad range of cytokines from blood is now commercially available in India, and marketed by the critical care division.

Research Services

The research services segment grew 25% YoY and 30% YoY at Constant Exchange Rate (CER) for H1 FY14 and Q2 FY14 respectively, with widespread growth across our service platforms.

Commenting on this performance, Peter Bains, Director Syngene International, said, *"The strong performance of research services in H1FY14 reflects the underlying strength of our diversified service offerings, which span the discovery and development continuum. This growth has been driven by a strong momentum in our manufacturing services platform along with a ramp up in our FTE contracts. Our continuous investments in capacities and capabilities have helped us enhance our end to end discovery, development and manufacturing offerings, in line with our clients' evolving requirements. We expect the current business momentum to continue supported by incremental investments, leading to a strong performance this fiscal."*

Outlook

The outlook for FY14 continues to be positive as we balance our revenue growth with R&D investments. We continue our efforts aimed at improving profitability with various cost control and portfolio optimization initiatives. The development portfolios spanning Biosimilars and novel molecules has moved further along the development cycle, and some of them will move into clinical trials shortly. Our current Capex commitments that include the Malaysia insulin plant are on track, and we continue to evaluate further investments to fuel future growth.

About Biocon

Established in 1978, Biocon Limited, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide. Biocon's robust product portfolio includes the world's first Pichia-based recombinant human Insulin, INSUGEN®, Glargine, BASALOG® and India's first biologic BioMAb-EGFR™ for head & neck cancer. It has now successfully developed its second novel biologic Itolizumab, a 'first in class' anti-CD6 monoclonal antibody, being introduced as Alzumab™ for psoriasis in India, in 2013. www.biocon.com

Disclaimer

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors, nor any of our affiliates, have any obligation to update or otherwise revise any statements reflecting

circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Earnings Call

The company will conduct an hour long call at **3:30 PM IST on October 25, 2013** where the senior management will discuss the company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below five to ten minutes ahead of the scheduled start time. The **dial-in number for this call is +91-22-6629 5889/ 3065 2542**. Other toll numbers are listed in the conference call invite which is posted on the company website www.biocon.com. The operator will provide instructions on asking questions before the start of the call. To receive reminders for the earnings call, you can register [here](#). A replay of this call will also be available from **October 25, 2013 – November 2, 2013** on the same dial-in numbers provided above. The transcript of the conference call will be posted on the company website within 7 working days of the investor conference call.

Encl.: Fact Sheet - Consolidated Income Statement and Balance Sheet (Indian GAAP)

Contact Information:

Investor Relations

Saurabh Paliwal
+91 95383 80801
saurabh.paliwal@biocon.com

Sweta Pachlangiya
+91 96865 09372
sweta.pachlangiya@syngeneintl.com

Media Relations

Seema Ahuja
+91 99723 17792
seema.ahuja@biocon.com

Rumman Ahmed
+91 98451 04173
rumman.ahmed@biocon.com

BIOCON GROUP

FACT SHEET

September - 2013

H1 FY 2014 vs. H1 FY 2013
Q2 FY 2014 vs. Q2 FY 2013

15/18

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT**

(Rs. Crores)

Particulars	H1 FY 14	H1 FY 13	Variance
INCOME			
Biopharmaceuticals *	886	734	21%
Branded formulations - India	200	178	12%
Total Biopharmaceuticals	1,086	912	19%
Contract research	343	252	36%
Total Sales	1,429	1,164	23%
Other income	39	71	-45%
Total Revenue	1,468	1,235	19%
EXPENDITURE			
Material & Power costs	678	570	19%
Staff costs	210	172	22%
Research & Development **	82	79	4%
Other expenses	135	109	24%
Manufacturing, staff & other expenses	1,105	930	19%
EBITDA	363	305	19%
Interest & Finance charges	1.00	4	
PBDT	362	301	20%
Depreciation & Amortisation	98	88	11%
PBT BEFORE EXCEPTIONAL ITEM	264	213	24%
Exceptional item, Net		-	
PBT	264	213	24%
Taxes	62	43	44%
NET PROFIT BEFORE MINORITY INTEREST	202	170	19%
Minority interest	6	1	
NET PROFIT FOR THE PERIOD	196	169	16%
EPS Rs.	9.8	8.5	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharmaceuticals Income includes:			
Licensing Income	11	14	
** Gross Research & Development expenses	91	100	

16/18

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT**

(Rs. Crores)

Particulars	Q2 FY 14	Q2 FY 13	Variance
INCOME			
Biopharmaceuticals *	447	372	20%
Branded formulations - India	99	91	9%
Total Biopharmaceuticals	546	463	18%
Contract research	188	129	46%
Total Sales	734	592	24%
Other income	19	50	-62%
Total Revenue	753	642	17%
EXPENDITURE			
Material & Power costs	335	291	15%
Staff costs	103	88	17%
Research & Development **	39	43	-9%
Other expenses	88	54	63%
Manufacturing, staff & other expenses	565	476	19%
EBITDA	188	166	13%
Interest & Finance charges	1	1	
PBDT	187	165	13%
Depreciation & Amortisation	49	45	9%
PBT BEFORE EXCEPTIONAL ITEM	138	120	15%
Exceptional item, Net		-	
PBT	138	120	15%
Taxes	33	30	10%
NET PROFIT BEFORE MINORITY INTEREST	105	90	16%
Minority interest	3	-	
NET PROFIT FOR THE PERIOD	102	90	13%
EPS Rs.	5.1	4.5	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharmaceuticals Income includes:			
Licensing Income	3	-	
** Gross Research & Development expenses	45	51	

17/18

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
BALANCE SHEET**

(Rs. Crores)

	September 30, 2013	March 31, 2013
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b) Reserves and surplus	2,830	2,595
	2,930	2,695
Minority interest	71	65
Non-current liabilities		
(a) Long-term borrowings	335	164
(b) Deferred tax liability (net)	36	41
(c) Other long-term liabilities	488	424
(d) Long-term provisions	6	4
	865	633
Current liabilities		
(a) Short-term borrowings	69	85
(b) Trade payables	394	345
(c) Other current liabilities	338	347
(d) Short-term provisions	104	246
	905	1,023
TOTAL	4,771	4,416
ASSETS		
Non-current assets		
(a) Fixed assets	2,047	1,811
(b) Good will	12	12
(c) Non-current investments	65	64
(d) Long term loans and advances	303	248
(e) Other non-current assets	52	41
	2,479	2,176
Current assets		
(a) Current Investments	476	522
(b) Inventories	422	398
(c) Trade receivables	583	510
(d) Cash and cash equivalents	658	673
(e) Short term loans and advances	64	81
(f) Other current assets	89	56
	2,292	2,240
TOTAL	4,771	4,416

18/18